Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Cancer Res. 2020 Mar 10;80(11):2298–2310. doi: 10.1158/0008-5472.CAN-19-3133

Figure 6. STM418 enhances T-cell proliferation and activation in vitro.

Figure 6.

(A) Quantification of the proliferation of NCI-H226 cells co-cultured with T cells isolated from PMBCs in the presence or absence of STM418 (20 μg/mL). (B) Flow cytometric analysis of the proliferation of CFSE-labeled T cells co-cultured with dendritic cells (DCs) in the presence or absence of STM418 (10 μg/mL). (C) Quantification of IL-2 levels by ELISA. Experiments were conducted as described in (B). Supernatants were collected on day 5 and subjected to ELISA. (D) Normalized luminescence of PD-1 expressing Jurkat T cells transiently transfected with an NFAT-Luc reporter construct and stimulated with α-CD3/CD28/IgG or α-CD3/CD28/PD-L1 in the presence or absence of STM418 (20 μg/mL). (E) Flow cytometric analysis of the proliferation of CFSE-labeled T cells co-cultured with dendritic cells (DCs) in the presence of the indicated dose of IgG, STM418, nivolumab, or pembrolizumab. (F) Quantification of IFNγ levels by ELISA. Experiments were conducted as described in (E). Supernatants were collected on day 5 and subjected to ELISA. All data represent mean ± SD from at least three independent experiments. *, P < 0.05.